TIGIT dual blockade with PD-1, PD-L1, or TIM-3 has a synergistic action that produces enhanced CD8+ T cell activity and tumor regression in a colorectal carcinoma model [61]. The gene discussed is HAVCR2; the disease is neoplasm.